| Antagomir technology in the treatment of different types of cancer KA Preethi, G Lakshmanan, D Sekar Epigenomics 13 (07), 481-484, 2021 | 280 | 2021 |
| Dietary microRNAs: Current status and perspective in food science KA Preethi, D Sekar Journal of Food Biochemistry 45 (7), e13827, 2021 | 248 | 2021 |
| Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer KA Preethi, SC Selvakumar, K Ross, S Jayaraman, D Tusubira, D Sekar Molecular Cancer 21 (1), 54, 2022 | 84 | 2022 |
| CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer SC Selvakumar, KA Preethi, K Ross, D Tusubira, MWA Khan, P Mani, ... Molecular Cancer 21 (1), 83, 2022 | 37 | 2022 |
| Defending against web vulnerabilities and cross-site scripting TVN Rao Journal of Global Research in Computer Science 3 (5), 61-64, 2012 | 15 | 2012 |
| Antagomir technology in the treatment of different types of cancer. Epigenomics [Internet]. 2021 Apr; 13 (7): 481–4 KA Preethi, G Lakshmanan, D Sekar | 15 | |
| Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics SC Selvakumar, J Selvaraj, U Mony, VP Veeraraghavan, D Sekar, ... Oral oncology 125, 105713, 2022 | 11 | 2022 |
| MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways SC Selvakumar, KA Preethi, D Sekar Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 188904, 2023 | 7 | 2023 |
| Therapeutic nature of microRNAs in oral squamous cell carcinoma (OSCC) D Sekar, SC Selvakumar, KA Preethi Oral oncology 134, 106106, 2022 | 7 | 2022 |
| MicroRNAs in the epigenetic regulation of disease progression in Parkinson’s disease SC Selvakumar, KA Preethi, D Tusubira, D Sekar Frontiers in Cellular Neuroscience 16, 995997, 2022 | 7 | 2022 |
| Antagomir technology in the treatment of different types of cancer [Internet]. Vol. 13, Epigenomics. 2021 KA Preethi, K Auxzilia Preethi, G Lakshmanan, D Sekar | 5 | |
| MicroRNAs and cancer-associated fibroblasts in the tumour microenvironment of oral squamous cell carcinoma (OSCC) SC Selvakumar, KA Preethi, D Sekar Oral oncology 134, 106124, 2022 | 3 | 2022 |
| MicroRNAs and it's targets in the treatment of salivary adenoid cystic carcinoma KA Preethi, SC Selvakumar, D Sekar Oral oncology 133, 106053, 2022 | 3 | 2022 |
| Diagnostic and Therapeutic Application of Exosomal microRNAs Inducing Inflammation in Type 2 Diabetes Mellitus KA Preethi, SC Selvakumar, D Sekar Critical Reviews™ in Immunology 42 (1), 2022 | 3 | 2022 |
| Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications KA Preethi, SC Selvakumar, K Ross, D Sekar Gene Reports 29, 101676, 2022 | 2 | 2022 |
| Future of Human Security Based on Computational Intelligence Using Palm Vein Technology TV Rao, K Preethi Global Journal of Computer Science and Technology 10 (10), 68-73, 2010 | 2 | 2010 |
| Expression profiling of signal transducer and activator of transcription3 in oral squamous cell carcinoma in south Indian population. P Thomas, SC Selvakumar, KA Preethi, D Sekar Minerva Dental and Oral Science, 2023 | 1 | 2023 |
| Relevance of micro-RNAs and their targets as a diagnostic and prognostic marker in oral squamous cell carcinoma P Thomas, KA Preethi, SC Selvakumar, P Ramani, D Sekar Journal of Oral and Maxillofacial Pathology 27 (2), 364-373, 2023 | 1 | 2023 |
| Non-coding RNAs influencing anti PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC) SC Selvakumar, KA Preethi, D Sekar Oral oncology 134, 106092, 2022 | 1 | 2022 |
| Theragnostic implications of exosomes in preeclampsia SC Selvakumar, D Sekar, KA Preethi, S Jayaraman Hypertension Research 45 (1), 178-180, 2022 | 1 | 2022 |
